UPDATE 1-Gavreto wins conditional EU approval to treat form of lung cancer -Roche [Reuters]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Reuters
By Reuters Staff 2 Min Read ZURICH (Reuters) -Roche’s Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, the Swiss drugmaker said on Friday. Gavreto, known generically as pralsetinib, is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC. Around 37,500 people are diagnosed with RET fusion-positive NSCLC worldwide each year, it said here in a statement. Blueprint Medicines and Roche are co-developing Gavreto globally, with the exception of certain territories in Asia, including China. Blueprint Medicines and Roche unit Genentech are commercialising Gavreto in the United States, and Roche has exclusive commercialisation rights for Gavreto outside the United States, with the exception of some parts of Asia. CStone Pharmaceuticals retains rights to the development and commercialisation of Gavreto in mainland China, Taiwan, Hong Kong and Mac
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsPR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? [Yahoo! Finance]Yahoo! Finance
BPMC
Earnings
- 2/15/24 - Beat
BPMC
Sec Filings
- 4/10/24 - Form SC
- 4/1/24 - Form 4
- 3/28/24 - Form 144
- BPMC's page on the SEC website